Navigation Links
Verenium to Present at Upcoming Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced James Levine, President and Chief Executive Officer, will present at two upcoming conferences.

Mr. Levine will present at the upcoming Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011.  The presentation is expected to begin at 1:35 p.m. ET and will take place at the Waldorf=Astoria Hotel in New York City.  

Mr. Levine will also present at the upcoming Wedbush 2011 Clean Technology & Industrial Growth Conference on Thursday, September 15, 2011.  The presentation is expected to begin at 3:00 p.m. PT and will take place at The Westin in San Francisco, California.

Live webcasts of both presentations may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com.  A webcast replay will be available approximately one hour after the live webcasts end and will be accessible for 30 days following these conferences.  

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011
2. Verenium Announces Debt Repurchase
3. Verenium Announces Signing of Lease for New Office and Lab Space
4. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
5. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
6. Verenium to Present at Upcoming Conferences
7. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
8. Verenium to Present at MDB Capital Groups Bright Lights Conference
9. Verenium Announces Debt Repurchase
10. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... - Researchers are making progress in creating digital transistors ... thought to dramatically limit the material,s use in computers ... of carbon that conducts electricity with little resistance or ... earned a Nobel Prize in physics - it was ...
... was named by FierceBiotech today as one of 2011,s ... promising private biotechnology companies in the industry. This is FierceBiotech,s ... has done a super job of raising the funds and ... combination therapy – toward the market," says Ryan McBride, the ...
... Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 ... today that data from two studies, a Phase II ... compound custirsen (OGX-011/TV-1011), were published in the September issues ... Cancer Research . Custirsen inhibits ...
Cached Biology Technology:Innovation is step toward digital graphene transistors 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 2OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 4OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 5
(Date:9/18/2014)... of carbon and nitrogen comprise all spheres of ... systems have caused imbalances and perturbations that resulted ... Increased GHGs result in climate changes which influence ... and the atmosphere. Understanding these feedback mechanisms has ... environmental science during the past three decades. , ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... Bethesda, MD This FASEB Science Research Conference ... of intestinal lipid digestion and absorption with new ... to understanding the mechanisms of health maintenance and ... resistance and diabetes, dyslipidemia, intestinal failure and gastrointestinal ...
... Conference focuses on recent advances in the methods for ... to promote the discovery and exchange of new methods ... facilitate the application of methods in protein structure analysis ... to support and foster the education of researchers in ...
... from Iowa State University (USA) published a study which ... metals. Now, a team from the University of the ... results throw this discovery into question. This has reaffirmed ... validity in the press. The resistance and elasticity ...
Cached Biology News:Spider silk ties scientists up in knots 2
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: